Lacto-N-fucopentaose III, a Pentasaccharide, Prolongs Heart Transplant Survival
- 27 November 2010
- journal article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 90 (10) , 1071-1078
- https://doi.org/10.1097/tp.0b013e3181f8f296
Abstract
Lacto-N-fucopentaose III (LNFPIII) is a pentasaccharide containing the Lewis(x) trisaccharide that is found on schistosome eggs and in breast milk. LNFPIII conjugates suppress host immune responses and have therapeutic efficacy in mouse models of psoriasis and type 1 diabetes. We used nonvascularized neonatal ear-heart transplantation and heterotopic vascularized heart transplantation models to evaluate immunosuppressive effects of LNFPIII and subsequently analyzed the mechanism. We found that administration of LNFPIII conjugates prolonged median graft survival by 80% when 1-day-old DBA/2 hearts were transplanted into ears of B6 mice. A similar graft prolongation was observed in a fully vascularized heterotopic heart transplantation model (DBA/2 into B6), No prolongation was observed with carrier protein (human serum albumin [HSA] or dextran) alone. We found increased programmed death ligand 1 (PD-L1) expression on F4/80 macrophages, CD4+ T cells, and CD11b+ CD11c+ (myeloid) dendritic cells, and increased arginase1 and Ym1 expression, typical of alternatively activated macrophages, in the draining (cervical) lymph node cells. We found accumulation of Foxp3+ regulatory T cells (Tregs) in the lymph nodes draining donor hearts, suggesting a possible role of Treg induction in graft prolongation. Anti-PD-L1 antibody treatment abrogated LNFPIII-mediated the graft survival benefit and Treg accumulation. LNFPIII-treated macrophages had increased PD-L1 expression and significantly prolonged DBA/2 allograft survival when injected intraperitoneally into B6 recipient mice. LNFPIII prolongs fully allogeneic graft survival in both vascularized and nonvascularized allograft transplantation models. The mechanism of graft prolongation seems to involve both alternatively activated PDL-1 macrophages and recruitment of Foxp3+ Treg cells.Keywords
This publication has 18 references indexed in Scilit:
- The immunomodulatory glycan LNFPIII initiates alternative activation of murine macrophages in vivoImmunology, 2008
- Macrophage activation and polarizationFrontiers in Bioscience-Landmark, 2008
- Optimal induction of T helper 17 cells in humans requires T cell receptor ligation in the context of Toll-like receptor-activated monocytesProceedings of the National Academy of Sciences, 2007
- Alternatively activated macrophages in helminth infectionsCurrent Opinion in Immunology, 2007
- The Novel JAK-3 Inhibitor CP-690550 Is a Potent Immunosuppressive Agent in Various Murine ModelsAmerican Journal of Transplantation, 2004
- Cutting Edge: Carbohydrate Profiling Identifies New Pathogens That Interact with Dendritic Cell-Specific ICAM-3-Grabbing Nonintegrin on Dendritic CellsThe Journal of Immunology, 2003
- Alternative activation of macrophagesNature Reviews Immunology, 2003
- A Schistosome-Expressed Immunomodulatory Glycoconjugate Expands Peritoneal Gr1+ Macrophages That Suppress Naive CD4+ T Cell Proliferation Via an IFN-γ and Nitric Oxide-Dependent MechanismThe Journal of Immunology, 2001
- Selectin ligands.Proceedings of the National Academy of Sciences, 1994
- A Schistosoma mansoni epitope recognized by a protective monoclonal antibody is identical to the stage-specific embryonic antigen 1.Proceedings of the National Academy of Sciences, 1990